Crystal A. Mendoza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Crystal A. Mendoza has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Hideki Ebihara
Department of Virology I, National Institute of Infectious Diseases, Japan Institute for Health Security, Musashimurayama-shi, Japan
1 shared publication - Satoko Yamaoka
Department of Medicine, Division of Infectious Diseases, Mayo Clinic
1 shared publication
Latest Publications
- Open Access
Immune Modulation and Immune-Mediated Pathogenesis of Emerging Tickborne Banyangviruses
In the last decade, the emergence of several, novel tickborne viruses have caused significant disease in humans. Of interest are the tickborne banyangviruses: Severe fever with thrombocytopenia syndrome virus (SFTSV), Heartland virus (HRTV), and Guertu virus (GTV). SFTSV and HRTV infection in humans cause viral hemorrhagic fever-like disease leading to mortality rates ranging from 6–30% of the cases. The systemic inflammatory response syndrome (SIRS) associated with SFTSV infection is hypothesized to contribute significantly to pathology seen in patients. Despite the severe disease caused by HRTV and SFTSV, there are no approved therapeutics or vaccines. Investigation of the immune response during and following infection is critical to the generation of fully protective vaccines and/or supportive treatments, and overall understanding of viral immune evasion mechanisms may aid in the development of a new class of therapeutics.
Open AccessImmune Modulation and Immune-Mediated Pathogenesis of Emerging Tickborne Banyangviruses
In the last decade, the emergence of several, novel tickborne viruses have caused significant disease in humans. Of interest are the tickborne banyangviruses: Severe fever with thrombocytopenia syndrome virus (SFTSV), Heartland virus (HRTV), and Guertu virus (GTV). SFTSV and HRTV infection in humans cause viral hemorrhagic fever-like disease leading to mortality rates ranging from 6–30% of the cases. The systemic inflammatory response syndrome (SIRS) associated with SFTSV infection is hypothesized to contribute significantly to pathology seen in patients. Despite the severe disease caused by HRTV and SFTSV, there are no approved therapeutics or vaccines. Investigation of the immune response during and following infection is critical to the generation of fully protective vaccines and/or supportive treatments, and overall understanding of viral immune evasion mechanisms may aid in the development of a new class of therapeutics.